She has a history of writing reports that clearly are very poorly researched. Jianping Song is a key player and it's very difficult to miss his strategic role in Artepharm Company and Artepharm Global. I wonder who pays for some of her reports to be written?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.